Different blood biomarkers may fit different purposes in a health care system that integrates screening, diagnosis, prognostication, and treatment monitoring. Different blood biomarkers are already validated for some of these purposes, while others remain emerging or potentially useful.
Related content
Advances in blood biomarkers are transforming the diagnosis and prognosis of Alzheimer’s disease, helping to assess pathology, disease progression, and co-existing pathologies.
Overview of a plasma biomarker testing pathway for symptomatic Alzheimer’s disease, using p-tau217 and eMTBR-tau243 to guide diagnostic assessment and identify underlying pathology.
Overview of blood-based biomarkers that capture distinct aspects of Alzheimer’s disease pathology and progression.